Variation of vector quantisation and speech waveform coding

A new idea for waveform coding using vector quantisation (VQ) is introduced. This idea makes it possible to deal with codevectors much larger than before for a fixed bit per sample rate. Also a solution to the matching problem (inherent in the present context) in the &-norm describing a measure of neamess is presented. The overall computational complexity of this solution is O(n3 log, n). Sample results are presented to demonstrate the advantage of using this technique in the context of coding of speech waveforms.

Computations of Vector-Valued Siegel Modular Forms

We carry out some computations of vector-valued Siegel modular forms of degree two, weight (k, 2) and level one, and highlight three experimental results: (1) we identify a rational eigenform in a three-dimensional space of cusp forms; (2) we observe that non-cuspidal eigenforms of level one are not always rational; (3) we verify a number of cases of conjectures about congruences between classical modular forms and Siegel modular forms. Our approach is based on Satoh's description of the module of vector-valued Siegel modular forms of weight (k, 2) and an explicit description of the Hecke action on Fourier expansions. (C) 2013 Elsevier Inc. All rights reserved.

Parvovirus 4 infection and clinical outcome in high-risk populations

Parvovirus 4 (PARV4) is a DNA virus frequently associated with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections, but its clinical significance is unknown. We studied the prevalence of PARV4 antibodies in 2 cohorts of HIV- and HCV-infected individuals (n = 469) and the correlations with disease status. We found that PARV4 infection frequently occurred in individuals exposed to bloodborne viruses (95% in HCV-HIV coinfected intravenous drug users [IDUs]). There were no correlations between PARV4 serostatus and HCV outcomes. There was, however, a significant association with early HIV-related symptoms, although because this was tightly linked to both HCV status and clinical group (IDU), the specific role of PARV4 is not yet clear.